| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNISA990001120330203316 |
|
|
Autore |
ADAMS, Henry |
|
|
Titolo |
The education of Henry Adams : an autobiography / Henry Adams ; with a new introduction by Marion L. Starkey |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
New York : Time incorporated, 1964 |
|
|
|
|
|
|
|
Descrizione fisica |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Collocazione |
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
2. |
Record Nr. |
UNINA9910788696703321 |
|
|
Autore |
Austin Martin |
|
|
Titolo |
Licensing, selling and finance in the pharmaceutical and healthcare industries : the commercialization of intellectual property / / Martin Austin |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
London ; ; New York : , : Routledge, , 2016 |
|
|
|
|
|
|
|
ISBN |
|
1-317-10530-3 |
1-315-59234-7 |
1-283-62954-2 |
9786613941992 |
1-4094-5080-5 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (191 p.) |
|
|
|
|
|
|
Disciplina |
|
338.4/76606 |
338.476151 |
338.476606 |
615.10681 |
|
|
|
|
|
|
|
|
Soggetti |
|
Biotechnology industries |
Pharmaceutical industry |
Intellectual property |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
"A Gower book"--Cover. |
First published 2012 by Gower Publishing. |
|
|
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and index. |
|
|
|
|
|
|
Nota di contenuto |
|
pt. 1. The challenge -- pt. 2. Models and solutions. |
|
|
|
|
|
|
Sommario/riassunto |
|
Licensing, Selling and Finance in the Pharmaceutical and Healthcare Industries is an assessment of the turbulent state of pharmaceutical and biotechnology markets as we enter the second decade of the 21st Century. At the same time, the book offers a cautionary evaluation of the future financing of innovation in terms of what's gone wrong and how to succeed in the future.Martin Austin explores the challenge that the pharmaceutical (and related) industries face in terms of balancing short term, cost containment and expenditure control in areas such as internal research and development; whilst em |
|
|
|
|
|
|
|
| |